PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
118.91%
Cash & equivalents changing by 118.91% while Biotechnology maintains stable levels. Benjamin Graham would examine if this divergence is justified.
No Data
No Data available this quarter, please select a different quarter.
118.91%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.59%
Current assets growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
15.06%
PP&E growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
15.06%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
104.51%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
55.57%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
719.98%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
14812.60%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
4364.90%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
91.77%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-19849.13%
≥ 1.5x Biotechnology median of -0.89%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1201.65%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.16%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-119.69%
Above 1.5x Biotechnology median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.